Bristol-Myers Squibb announces phase 3 CheckMate -331 study does not meet primary endpoint
Bristol-Myers Squibb announced topline results from the Phase 3 CheckMate -331 study evaluating Opdivo (nivolumab) versus the current standard of care, topotecan or amrubicin), in patients with SCLC. The study did not meet its primary endpoint of OS with Opdivo versus chemotherapy. October 12, 2018